High-Risk Human Papillomavirus Detection via Cobas<sup>®</sup> 4800 and REBA HPV-ID<sup>®</sup> Assays
2022
Sasiprapa Liewchalermwong | Shina Oranratanaphan | Wichai Termrungruanglert | Surang Triratanachat | Patou Tantbirojn | Nakarin Kitkumthorn | Parvapan Bhattarakosol | Arkom Chaiwongkot
Persistent infection with high-risk human papillomaviruses (HR-HPVs), particularly HPV16 and 18, has long been known to induce cervical cancer progression. However, given that a minority of HPV-infected women develop cancer, analysis of HR-HPV-infected women could help to predict who is at risk of acquiring cervical cancer. Therefore, to improve HR-HPVs detection, we used the FDA-approved cobas<sup>®</sup> 4800 HPV and REBA HPV-ID<sup>®</sup> HPV assays to detect HR-HPVs in colposcopy-derived cervical cells from 303 patients, detecting 72.28% (219) and 71.62% (217) of HR-HPVs positive cases, with HPV16 detection rates of 35.64% (108) and 30.69% (93), respectively. Of the HPV16-positive cases, cobas<sup>®</sup> 4800 and REBA HPV-ID<sup>®</sup> identified 28.81% (51) and 25.42% (45) of the CIN1 cases, and 55% (33) and 50% (30) of the 60 CIN2/3 cases, respectively. HPV-diagnostic concordance was 82.17% overall (kappa = 0.488), 87.45% for HR-HPVs (kappa = 0.689), and 88.33% for CIN2/3 (kappa = 0.51). The HR-HPVs detection rates of these assays were comparable. Our findings reveal that the FDA-approved HR-HPVs detection assay is appropriate for screening women with HR-HPVs infection, and for predicting increased risk of cervical cancer progression. REBA HPV-ID<sup>®</sup> can be used to detect low risk-HPV types in high-grade cervical lesions that are HR-HPV negative as well as in the distribution of HPV types.
Show more [+] Less [-]Bibliographic information
This bibliographic record has been provided by Directory of Open Access Journals